Presentation after next 2 weeks ( c, b ): in control rats, drinking water was continuously given (12 ml/day/rat) (defecation through fistula, c ) and in BPC 157 rats, BPC 157 (10 g/kg/day) was given in drinking water (0.16 g/ml/day/rat) (fistula closed, b )
Given the immunogenic potential of protein-based drugs, it is important to monitor allergic reactions with GLP-1RAs
The starting dose considerations from your tirzepatide experience still inform your approach, but conservatism serves you well here
Start with a short online questionnaire and, if appropriate, a video or message-based visit with a licensed clinician
Comorbidities and Associated Health Conditions Beyond just BMI, BCBS will also check if you have any comorbidities